DURHAM, N.C.--(BUSINESS WIRE)--BioAgilytix, a leading provider of contract bioanalytical testing services with specialization in large molecule bioanalysis, has announced the acquisition of IPM ...
FDA grants Breakthrough Device Designation to BioAgilytix’s anti-AAV antibody assay supporting Lexeo’s gene therapy for Friedreich ataxia. DURHAM, NC, UNITED ...
DURHAM, N.C., Jan. 4, 2021 /PRNewswire/ -- BioAgilytix Labs is pleased to announce the appointment of Marc Westermann to its commercial leadership team as Vice President of Business Development Europe ...